Navigation Links
deCODE Announces Positive Topline Results for Phase I Study of,DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi- dose, ascending dose, placebo-controlled clinical trial, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. Building upon the positive results seen in the Phase I single dose study completed at the end of last year, key results were:

Safety and tolerability: DG051 was well tolerated at all dose levels tested, with no serious adverse events reported.

Dose-dependent reduction of leukotriene B4 (LTB4): DG051 was shown to reduce LTB4 production in a dose-dependent manner, with a peak reduction of more than 70% versus baseline after 7 days of treatment.

Pharmacokinetic profile: DG051 was found to have good bioavailability, with low variability between subjects. With a terminal half-life of approximately 9 hours and measurable concentrations at 24 hours after dosing, DG051 has a pharmacokinetic profile suitable for once-a-day dosing.

"The results of our Phase I trials show DG051 to be well tolerated and to provide a potent means of reining in the activity of the pathway our research has shown to modulate risk of heart attack. This latest study also provides us with pharmacodynamic data suggesting that we may be able to achieve a high steady-state reduction in LTB4 production with a dose in the middle of the range we have tested, and we look forward to entering DG051 into Phase II trials later this year," said Kari Stefansson, CEO of deCODE.

About DG051

DG051 is a first-in-class, small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H) discovered by deCODE's chemistry unit and being developed for the prevention of heart attack. LTA4H is encod
'"/>




Page: 1 2 3

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... launches integrated, multi-channel offerings for three fast-growing export sectors -- HONG KONG, Oct. 26 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... Oct. 25 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended September 30, 2010, on Monday, November 1, ... will host a conference call and webcast on Monday, ... discuss the Company,s third quarter results and corporate developments. ...
Cached Medicine Technology:Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 2Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 3Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 4Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 5Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 6Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 7Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 8Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 9Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 2Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 3
(Date:9/30/2014)... 30, 2014 Dynamic health trends, ... growth in the Bread Production industry over the ... to moderate their consumption of a variety of ... varieties shrunk the market for white loaf bread ... responded by introducing more nutritious products to attract ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet ... Geary that is helping people learn the truth about so-called ... machine in less than 24 hours has caught the attention ... our culture that is becoming so obsessed with diets and ... really fact and fiction when it comes to health foods, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 For most ... the apple orchard, pumpkin patch or annual festival. For ... fast-spreading viruses – like the respiratory infection Enterovirus D68. ... most children, a small percentage – especially children with ... Increased concern about the Enterovirus is prompting hospitals across ...
(Date:9/30/2014)... September 30, 2014 A group of Americans ... combat an epidemic that, left unchecked, could create a catastrophic, ... not headed to Africa. John Rogers, the Executive Director the ... Korea to fight a disease most think mankind conquered long ... 80 years ago is on the comeback in several countries ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... ... biopsy techniques away from more invasive approaches toward imaging-guided percutaneous—or through the skin—techniques, according ... journal Radiology . , ... Oak Brook, IL (Vocus) June 29, 2010 -- Advanced imaging technologies ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... from several large clinical trials, the diabetes drug Avandia does ... argument that the drug,s risks might outweigh its benefits in ... however, show an increased risk for death from cardiovascular disease, ...
... HealthDay Reporter , MONDAY, June 28 (HealthDay News) -- ... drugs known as statins are a third less likely to ... that your doctor prescribe a statin -- drugs such ... The findings aren,t firm enough for doctors to make ...
... BROOK, Ill. Arthroscopic surgical repair of torn anterior cruciate ... not decrease the chances of developing osteoarthritis, according to a ... issue of the journal Radiology . A ... knee osteoarthritis was evident in patients, regardless of whether or ...
... children and teenagers for watching too much TV. It turns ... their time watching TV, and it is not good for ... Research on Aging and Rady School of Management at the ... a study published online in advance of publication in the ...
... review, led by Dr. Joseph Lee, published in the June 2010 ... Orthopaedic Surgeons ( JAAOS ) suggests that a herniated disk ... leg pain in adults, but surgery is not for everyone. ... pain at some point in their lives Disks, which are ...
Cached Medicine News:Health News:Use of Less Invasive, Imaging-Guided Biopsies on the Rise 2Health News:Use of Less Invasive, Imaging-Guided Biopsies on the Rise 3Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 2Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 3Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 4Health News:Statins May Lower Rates of Prostate Cancer Recurrence 2Health News:Surgical repair of knee injuries does not decrease risk of osteoarthritis 2Health News:Older adults watch more TV than younger people, enjoy it less 2Health News:Lower back pain and surgery 2
... Two Large Working Channels; 33 cm Working ... is the smallest ureteroscope with two large ... The ACMI MICRO-6 Ureteroscope reduces patient trauma ... or no dilation or general anesthesia. It ...
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
Semi-Rigid Ureteroscope...
... features a tip diameter of only ... up/down angulation range of 180 for ... areas.,For improved observation, a new optical ... reusable 11.7Fr (3.9mm) sheath dilator, 0.035" ...
Medicine Products: